3/13
11:35 am
cybn
Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]
Low
Report
Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited [Seeking Alpha]
3/13
07:50 am
cybn
Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
2/17
07:46 am
cybn
Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]
Low
Report
Podcast: How Trump's tariffs will impact clinical trials [Yahoo! Finance]
2/13
08:10 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at HC Wainwright from $190.00 to $150.00. They now have a "buy" rating on the stock.
2/12
08:52 am
cybn
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $86.00 to $73.00. They now have a "buy" rating on the stock.
2/10
09:48 pm
cybn
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Low
Report
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
1/27
01:44 pm
cybn
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Low
Report
Cybin Inc. (NYSE: CYBN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
1/22
01:39 pm
cybn
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
Low
Report
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight [Yahoo! Finance]
6/26/2024
07:31 am
cybn
cybin inc. common shares
MISS
Report
4.4%
cybin inc. common shares
2/14
06:29 pm
cybn
Form SCHEDULE 13G/A CYBIN INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SCHEDULE 13G/A CYBIN INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
2/14
05:13 pm
cybn
Form 6-K CYBIN INC. For: Feb 14
Medium
Report
Form 6-K CYBIN INC. For: Feb 14
2/14
04:00 pm
cybn
Form SCHEDULE 13G/A CYBIN INC. Filed by: TANG CAPITAL MANAGEMENT LLC
Low
Report
Form SCHEDULE 13G/A CYBIN INC. Filed by: TANG CAPITAL MANAGEMENT LLC
2/11
06:31 am
cybn
Form 6-K CYBIN INC. For: Feb 10
Low
Report
Form 6-K CYBIN INC. For: Feb 10
2/11
06:30 am
cybn
Form SUPPL CYBIN INC.
Low
Report
Form SUPPL CYBIN INC.
2/11
06:01 am
cybn
Form 6-K CYBIN INC. For: Feb 10
Low
Report
Form 6-K CYBIN INC. For: Feb 10
1/15
03:29 pm
cybn
Form 6-K CYBIN INC. For: Jan 15
Low
Report
Form 6-K CYBIN INC. For: Jan 15
1/15
06:08 am
cybn
Form EFFECT CYBIN INC.
Low
Report
Form EFFECT CYBIN INC.
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register